Clinical impact of post-progression survival on overall survival in patients receiving nivolumab monotherapy as a second-line treatment for advanced non-small cell lung cancer.
Hisao ImaiOu YamaguchiKeita MoriKosuke HashimotoTomoe AkagamiShun ShinomiyaYu MiuraAyako ShionoAtsuto MouriKyoichi KairaKunihiko KobayashiHiroshi KagamuPublished in: Thoracic cancer (2021)
Our findings suggest that subsequent treatment for disease progression after a second-line nivolumab treatment had a significant impact on OS.